Credit Suisse Entrepreneur Capital co-led the insulin injection device developer’s latest round, participating alongside investors including Tandem Diabetes Care and Ypsomed.

UTEC has returned to co-lead a $14m funding round for ImmunoScape, which will use the money to bolster its presence in Singapore and the US.

IU Ventures has returned for a series B round for Encamp, having previously taken part in a series A round year.

Asahi Kasei Ventures took part in a $70m round for food waste technology provider Hazel Technologies while Zoll Medical Corporation bought portfolio company Respicardia.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Cambrian Biopharma, LG, GlaxoSmithKline, Novo and Takeda all invested in the cell therapy developer to help it close its series C round.

Taiho has reupped its commitment to the venture firm’s second fund, which is also backed by EA Pharma and Senju and which has closed at $95m.

UGA spinout Aruna Bio is working on a treatment for neurodegenerative diseases such as Parkinson’s and multiple sclerosis.

Vision Fund 2 participated in a series B round for the gene therapy developer, formed through the 2019 merger of Torque Therapeutics and Cogen Immune Medicine.

Vizgen co-founder David Walt, a professor at Harvard Medical School, has invested in the spinout as part of its series B round.